Please login to the form below

T790M mutation

This page shows the latest T790M mutation news and features for those working in and with pharma, biotech and healthcare.

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

for patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). ... Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit, AstraZeneca, said: “Tagrisso is

Latest news

AZ speeds first-line lung cancer filing for Tagrisso to EMA

Tagrisso has been growing fast in its approved indication as a second-line therapy for EGFR-positive NSCLC after patients develop resistance (the T790M mutation) and progress on Iressa or Tarceva, ... Conversely, others argue that this denies patients
AZ gets rapid approval in China for Tagrisso

Tagrisso (osimertinib) - a third-generation EGFR inhibitor - has been approved by the China Food and Drug Administration (CFDA) as a second-line treatment for EGFR T790M mutation-positive metastatic non-small ... Last December, AZ reported head-to-head
AZ's Tagrisso beats chemotherapy in lung cancer trial

to standard therapy in patients with T790M mutation-positive, locally-advanced or metastatic NSCLC. ... Tagrisso is a third-generation EGFR inhibitor and was the first drug to be approved to treat patients with metastatic EGFR T790M mutation-positive
Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

In the meantime, the recently-relaunched CDF will give around 300 patients across England and Wales access to Tagrisso as a second-line treatment for advanced metastatic EGFR T790M mutation-positive ... This is the system working as it should.”.
FDA panel says no to quick approval of Clovis' rociletinib

Rociletinib is under review for the treatment of non-small cell lung cancer (NSCLC) patients whose tumours are epidermal growth factor receptor (EGFR) positive and carry the T790M resistance mutation. ... T790M is the most commonly encountered and

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... The EGFR mutation is particularly prevalent in Asian populations
Interview: AstraZeneca's Susan Galbraith

resistance mechanisms for first and second generation inhibitors is the emergence of T790m, which basically switches on that same pathway again. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance